DRI Healthcare Trust (TSE:DHT.UN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of DRI Healthcare Trust (TSE:DHT.UN) have been assigned an average recommendation of “Moderate Buy” from the six ratings firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is C$17.94.

Several brokerages have weighed in on DHT.UN. CIBC cut their target price on DRI Healthcare Trust from C$19.50 to C$18.00 and set an “outperform” rating on the stock in a research note on Thursday, December 12th. Scotiabank upped their price objective on shares of DRI Healthcare Trust from C$21.00 to C$22.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th. Finally, Raymond James lowered their target price on shares of DRI Healthcare Trust from C$23.00 to C$22.00 in a research note on Wednesday, November 13th.

DRI Healthcare Trust Stock Performance

TSE DHT.UN opened at C$12.08 on Friday. DRI Healthcare Trust has a fifty-two week low of C$10.39 and a fifty-two week high of C$17.43. The business has a 50 day moving average price of C$12.34 and a two-hundred day moving average price of C$12.69.

About DRI Healthcare Trust

DRI Healthcare Trust is an open-ended trust that provides unitholders with differentiated exposure to the anticipated growth in the global pharmaceuticals and biotechnology markets. Its business model is focused on managing and growing a diversified portfolio of pharmaceutical royalties to deliver attractive growth in cash royalty receipts over the long term.